Meet the startups: Theraimmune

At Theraimmune, we are pioneering AI-driven therapeutic development for post-menopausal women, addressing a $1.1 trillion market opportunity. Our mission is to tackle the underlying disease processes before symptoms even appear.

By leveraging AI to discover novel drug targets that modulate immune function, reduce inflammation, and enhance resilience to age-related diseases, we are transforming healthcare by creating therapies that prevent, rather than just treat, age-related conditions.

AI is at the core of our business model at Theraimmune.

Our multi-architecture AI platform utilizes integrating multiple model types to analyze large datasets from diverse biological sources. These AI tools allow us to uncover complex interactions in immune aging, enabling us to identify robust drugs targeting the underlying disease mechanisms that are precise and effective.

This AI-driven process is central to our drug discovery platform and is designed to bring personalized, preventive therapies to an underserved population.

We are excited to join Northern Data Group’s AI Accelerator not only for the access to cutting-edge NVIDIA H100 GPUs, which will enable us to scale our computational analyses of biological networks, but also for the invaluable mentorship and support from industry leaders.

This guidance is crucial as we translate our research into scalable solutions and refine our business strategy. By participating in the AI Accelerator, we aim to push the boundaries of our research while leveraging expert advice to accelerate the development of breakthrough therapeutics for post-menopausal women.